Avi Biopharma
As of the edition of 20 October 2026, Avi Biopharma runs 18 drugs, 4 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Avi Biopharma was renamed in 1998.
- AVI BIOPHARMA, INC.: renamed in 1998
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 3 |
| Went quiet | 6 |
| Stopped | 4 |
| Status not established | 1 |
| Total | 18 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Eteplirsen | none listed | 0 |
| Golodirsen | Ends 2026 (exclusivity) | 0 |
| Casimersen | Ends 2030 (patent) | 0 |
| Delandistrogene moxeparvovec | Ends 2035 (reference-product exclusivity) | 0 |
A route B row is one company at one target.
Where its trials are
- Nervous system: 27 trials led
- Inherited and neonatal: 24 trials led
- Bones, joints and muscles: 23 trials led